Recap: Phathom Pharmaceuticals Q3 Earnings
Portfolio Pulse from Benzinga Insights
Phathom Pharmaceuticals (NASDAQ:PHAT) reported Q3 earnings, beating estimates by 14.61% with an EPS of $-0.76. However, revenue was down $0 from the same period last year. Last quarter, a beat on EPS was followed by a 0.67% drop in share price.
November 09, 2023 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Phathom Pharmaceuticals beat Q3 earnings estimates but saw no change in revenue from last year. Previous earnings beat led to a slight drop in share price.
While Phathom Pharmaceuticals beat earnings estimates, the lack of revenue growth and the historical trend of share price dropping after an earnings beat could lead to neutral or negative investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100